立优加 盐酸哌甲酯缓释片首发上市 立方制药持续发力高壁垒市场

Core Viewpoint - Lifan Pharmaceutical has launched its self-developed sustained-release methylphenidate hydrochloride tablets, marking a significant milestone in its product portfolio and reflecting its commitment to innovation in the pharmaceutical industry [1][2]. Group 1: Product Launch and Market Position - The sustained-release methylphenidate hydrochloride tablets, named Liyoujia, received drug registration certification in April 2023 and were officially launched on September 2, 2023 [1]. - This product is classified as a first-class psychotropic drug and is primarily used for treating Attention Deficit Hyperactivity Disorder (ADHD) [1]. - Currently, Lifan Pharmaceutical is one of the few domestic manufacturers of anesthetic and first-class psychotropic drugs, leveraging policy barriers and a comprehensive supply chain management to establish an integrated "R&D - Production - Distribution" model [1][2]. Group 2: Market Potential and Sales Performance - The prevalence of ADHD among adults in China is approximately 3%, while the rate among children is as high as 6.26%, indicating a significant market opportunity for methylphenidate formulations [2]. - The sales revenue of methylphenidate sustained-release tablets in domestic sample hospitals was about 350 million yuan in 2023, with an expected increase to approximately 430 million yuan in the first three quarters of 2024 [2]. - Following the product launch, Lifan Pharmaceutical has signed cooperation agreements with major pharmaceutical distribution companies to enhance the accessibility of Liyoujia across various medical institutions in China [2]. Group 3: R&D Investment and Strategic Focus - Lifan Pharmaceutical has been increasing its R&D investment, which is projected to reach 93.49 million yuan in 2024, accounting for 6.16% of its revenue [2]. - The company emphasizes that R&D is no longer viewed as a cost but as a core asset, focusing on products with technical, regulatory, and financial barriers to maintain a competitive edge [3]. - The strategic approach includes a dual focus on self-research and external collaborations to enhance its product pipeline and ensure predictable profitability in the Chinese market while participating in global innovation trends [3].